功能性消化不良药物治疗概述.pdfVIP

实用医药杂志201O年04月第27卷第40期PracJMed＆Phamr．Vol27．2010—40No．40·371·

[16】ReginsterJY，FelsenbergD，PavoI，eta1．Effectofraloxifene[21]SolomonDH，FinhelsteinJS，Wnagl~S，eta1．Statinlipidlowering

combinedwithmonofluorophosphateascomparedwithmono-drugsnadbonemineraldensity．PharmacoepidemiolDurgSaf,

fluorophosphatealoneinpostmenopausalwomenwithlowbone2005，14：219-226．

mass：arandomized,controlledtria1．OsteoporosInt,2003，14(9)：2【2】HatzigeorgiOHC，JacksonJL．Hydroxymehtylglutaryl-coenzyme

74l一749．Areductaseinhibitorsnadosteoporosis：ameta-naalysis．Oste-

[17】JnasDA，ThomasRJ，GillespieMT．Parathyroidhormone-re-oporosInt，2005，t6(8)：990-998．

latedprotein(PTHrP)：anucleocytoplasmicshuttlingproteinwith2【3】D’AmoreM，BottalieoC，D’AmoreS，eta1．Sexhomronesand

distinctpraacrineandintraerineroles．VitamHomr，2003，66：maleosteoporosis．Aphysiologicprospectiveforpreventionnad

345—384．therapy．MinervaMed，2000，91(3)：283-289．

1【8】UzawaT，HoriM，EjiriS，eta1．Comparisonoftheeffectsof[241KhoslaS，MeltonLJ，RobbReta1．Relationshipofvolumetric

intermittentnadcontinuousadministrationofhumanparathyroidBMDnadsturcturalparametersatdiffierentskeletalsitesto

hormone(1—34)onratbone．Bone，1995，164()：477_484．sexsteroidlevelsinmen．JBoneMinerRes，2005，20：730—

【19】CranneyA，PapaionanouA，ZytarukN，eta1．Praathyroidho740．

monefortherteatmentofosteoporosis：asystemartie-review．2【5】ReginsterJY，SeemnaE，DeVernejoulMC，eta1．Strontium

CMAJ，2006，175(1)：52—59．ranelatereducestheriskofnonvertebralfracturesinpostme—

[201HorwitzMJ，TedescoMB，GundbergC，eta1．Short-term,high—nopausalwomenwithosteoporosis：TreatmentofPeripheralOs—

dosepraathyroidhomrone-relatedproteinasaskeletalanabolieteoporosis(TROPOS)study．JClinEndocrinolMeta1)，2005，9O(5)：

agentofrthetreatmentof